Literature DB >> 23429692

Treatment for tobacco dependence: effect on brain nicotinic acetylcholine receptor density.

Arthur L Brody1, Alexey G Mukhin, Michael S Mamoun, Maggie Kozman, Jonathan Phuong, Meaghan Neary, Trinh Luu, Mark A Mandelkern.   

Abstract

Cigarette smoking leads to upregulation of brain nicotinic acetylcholine receptors (nAChRs), including the common α4β2* nAChR subtype. Although a substantial percentage of smokers receive treatment for tobacco dependence with counseling and/or medication, the effect of a standard course of these treatments on nAChR upregulation has not yet been reported. In the present study, 48 otherwise healthy smokers underwent positron emission tomography (PET) scanning with the radiotracer 2-FA (for labeling α4β2* nAChRs) before and after treatment with either cognitive-behavioral therapy, bupropion HCl, or pill placebo. Specific binding volume of distribution (VS/fP), a measure proportional to α4β2* nAChR density, was determined for regions known to have nAChR upregulation with smoking (prefrontal cortex, brainstem, and cerebellum). In the overall study sample, significant decreases in VS/fP were found for the prefrontal cortex, brainstem, and cerebellum of -20 (±35), -25 (±36), and -25 (±31)%, respectively, which represented movement of VS/fP values toward values found in non-smokers (mean 58.2% normalization of receptor levels). Participants who quit smoking had significantly greater reductions in VS/fP across regions than non-quitters, and correlations were found between reductions in cigarettes per day and decreases in VS/fP for brainstem and cerebellum, but there was no between-group effect of treatment type. Thus, smoking reduction and cessation with commonly used treatments (and pill placebo) lead to decreased α4β2* nAChR densities across brain regions. Study findings could prove useful in the treatment of smokers by providing encouragement with the knowledge that decreased smoking leads to normalization of specific brain receptors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23429692      PMCID: PMC3682149          DOI: 10.1038/npp.2013.53

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  64 in total

1.  Dynamic effects of self-efficacy on smoking lapse and relapse.

Authors:  S Shiffman; M H Balabanis; J A Paty; J Engberg; C J Gwaltney; K S Liu; M Gnys; M Hickcox; S M Paton
Journal:  Health Psychol       Date:  2000-07       Impact factor: 4.267

2.  Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors.

Authors:  L M Marubio; A M Gardier; S Durier; D David; R Klink; M M Arroyo-Jimenez; J M McIntosh; F Rossi; N Champtiaux; M Zoli; J-P Changeux
Journal:  Eur J Neurosci       Date:  2003-04       Impact factor: 3.386

3.  Bupropion is a nicotinic antagonist.

Authors:  J E Slemmer; B R Martin; M I Damaj
Journal:  J Pharmacol Exp Ther       Date:  2000-10       Impact factor: 4.030

Review 4.  Desensitization of neuronal nicotinic receptors.

Authors:  Michael W Quick; Robin A J Lester
Journal:  J Neurobiol       Date:  2002-12

5.  Nicotine blood levels and subjective craving for cigarettes.

Authors:  M E Jarvik; D C Madsen; R E Olmstead; P N Iwamoto-Schaap; J L Elins; N L Benowitz
Journal:  Pharmacol Biochem Behav       Date:  2000-07       Impact factor: 3.533

6.  Chronic treatments with tacrine and (-)-nicotine induce different changes of nicotinic and muscarinic acetylcholine receptors in the brain of aged rat.

Authors:  X Zhang; J-Y Tian; A-L Svensson; Z-H Gong; B Meyerson; A Nordberg
Journal:  J Neural Transm (Vienna)       Date:  2002-03       Impact factor: 3.575

7.  Bupropion for smoking cessation : predictors of successful outcome.

Authors:  L C Dale; E D Glover; D P Sachs; D R Schroeder; K P Offord; I T Croghan; R D Hurt
Journal:  Chest       Date:  2001-05       Impact factor: 9.410

8.  Measures of abstinence in clinical trials: issues and recommendations.

Authors:  John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan
Journal:  Nicotine Tob Res       Date:  2003-02       Impact factor: 4.244

9.  Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2-18F-FA-85380.

Authors:  Alexey G Mukhin; Alane S Kimes; Svetlana I Chefer; John A Matochik; Carlo S Contoreggi; Andrew G Horti; D Bruce Vaupel; Olga Pavlova; Elliot A Stein
Journal:  J Nucl Med       Date:  2008-09-15       Impact factor: 10.057

10.  Up-regulation of nicotinic acetylcholine receptors in menthol cigarette smokers.

Authors:  Arthur L Brody; Alexey G Mukhin; Jaime La Charite; Karen Ta; Judah Farahi; Catherine A Sugar; Michael S Mamoun; Evan Vellios; Meena Archie; Maggie Kozman; Jonathan Phuong; Franca Arlorio; Mark A Mandelkern
Journal:  Int J Neuropsychopharmacol       Date:  2012-11-21       Impact factor: 5.176

View more
  14 in total

1.  Decreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine Metabolism.

Authors:  Jacob G Dubroff; Robert K Doot; Mary Falcone; Robert A Schnoll; Riju Ray; Rachel F Tyndale; Arthur L Brody; Catherine Hou; Alexander Schmitz; Caryn Lerman
Journal:  J Nucl Med       Date:  2015-08-13       Impact factor: 10.057

2.  Brain nicotinic acetylcholine receptor availability and response to smoking cessation treatment: a randomized trial.

Authors:  Arthur L Brody; Alexey G Mukhin; Michael S Mamoun; Trinh Luu; Meaghan Neary; Lidia Liang; Jennifer Shieh; Catherine A Sugar; Jed E Rose; Mark A Mandelkern
Journal:  JAMA Psychiatry       Date:  2014-07-01       Impact factor: 21.596

3.  Changes in the α4β2* nicotinic acetylcholine system during chronic controlled alcohol exposure in nonhuman primates.

Authors:  Ansel T Hillmer; Dana L Tudorascu; Dustin W Wooten; Patrick J Lao; Todd E Barnhart; Elizabeth O Ahlers; Leslie M Resch; Julie A Larson; Alexander K Converse; Colleen F Moore; Mary L Schneider; Bradley T Christian
Journal:  Drug Alcohol Depend       Date:  2014-02-15       Impact factor: 4.492

Review 4.  Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date.

Authors:  Michael Mamoun; Andrew W Bergen; Jennifer Shieh; Anna Wiggins; Arthur L Brody
Journal:  CNS Drugs       Date:  2015-05       Impact factor: 5.749

Review 5.  The epidemiology of lung cancer.

Authors:  Patricia M de Groot; Carol C Wu; Brett W Carter; Reginald F Munden
Journal:  Transl Lung Cancer Res       Date:  2018-06

6.  Combination Extended Smoking Cessation Treatment Plus Home Visits for Smokers With Schizophrenia: A Randomized Controlled Trial.

Authors:  Arthur L Brody; Todd Zorick; Robert Hubert; Gerhard S Hellemann; Shabnam Balali; Sarah S Kawasaki; Lizette Y Garcia; Ryutaro Enoki; Paul Abraham; Paulina Young; Charles McCreary
Journal:  Nicotine Tob Res       Date:  2016-08-03       Impact factor: 4.244

Review 7.  Targeting brain α7 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status.

Authors:  Ana Sofía Vallés; María Virginia Borroni; Francisco J Barrantes
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

Review 8.  Bidirectional Associations among Nicotine and Tobacco Smoke, NeuroHIV, and Antiretroviral Therapy.

Authors:  Shivesh Ghura; Robert Gross; Kelly Jordan-Sciutto; Jacob Dubroff; Robert Schnoll; Ronald G Collman; Rebecca L Ashare
Journal:  J Neuroimmune Pharmacol       Date:  2019-12-13       Impact factor: 4.147

9.  Antidepressants for smoking cessation.

Authors:  Seth Howes; Jamie Hartmann-Boyce; Jonathan Livingstone-Banks; Bosun Hong; Nicola Lindson
Journal:  Cochrane Database Syst Rev       Date:  2020-04-22

10.  Preparation, Optimization, and Screening of the Effect of Processing Variables on Agar Nanospheres Loaded with Bupropion HCl by a D-Optimal Design.

Authors:  Jaleh Varshosaz; Mohammad Reza Zaki; Mohsen Minaiyan; Jaafar Banoozadeh
Journal:  Biomed Res Int       Date:  2015-05-19       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.